Organisation paid for research Program year 2025 Source: CMS Open Payments

Columbus Regional Research Ins

Neither a doctor nor a teaching hospital

Research payments

$60,512

37 payments

Through program year 2025, Columbus Regional Research Ins is reported as receiving $60,512 in research payments, across 37 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $6,490 3
2024 Research $30,740 6
2023 Research $17,400 2
2022 Research $3,017 8
2021 Research $2,864 18

Breakdown

Who paid Research payments · program years 2021–2025
  1. Sumitomo Pharma America, Inc. $54,630 11 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $5,882 26 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $54,630 11 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus $5,882 26 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record